CMET-19. CLINICAL RISK ASSESSMENT SCORE TO ESTIMATE THE LIKELIHOOD OF PSEUDOPROGRESSION VERSUS TUMOR GROWTH FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES. (5th November 2018)
- Record Type:
- Journal Article
- Title:
- CMET-19. CLINICAL RISK ASSESSMENT SCORE TO ESTIMATE THE LIKELIHOOD OF PSEUDOPROGRESSION VERSUS TUMOR GROWTH FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES. (5th November 2018)
- Main Title:
- CMET-19. CLINICAL RISK ASSESSMENT SCORE TO ESTIMATE THE LIKELIHOOD OF PSEUDOPROGRESSION VERSUS TUMOR GROWTH FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES
- Authors:
- Skeie, Bente
Øyvind Enger, Per
Pedersen, Paal-Henning
Olve Skeie, Geir - Abstract:
- Abstract: A major challenge in the follow-up of patients managed with stereotactic radiosurgery (SRS) brain for metastases (BM) is to differentiate pseudoprogression (PP) from tumor recurrence (TR). A clinical score based on tumor and treatment related factors would be valuable when selecting appropriate treatment. Follow-up images of 97 consecutive patients treated with SRS for 406 BM were analyzed. We included 100 (24.6 %) BM in 42 (43.3 %) patients which responded either with TR (delayed growth; 53 (13.1 %) BM in 27 patients) or PP (temporary volume increase; 47 (11.6 %) BM in 15 patients). Differences between the 2 groups were analyzed and used to develop a PP risk assessment score (PP-RAS). Significant factors associated with a higher incidence of PP versus TR were: primary lung cancer vs. other primaries, BM volume < 2cc (or BM < 1.5 cm in diameter), Target cover ratio ≥ 98 % and prior radiation with SRS or WBRT. Based on the presence (0) or not (1) of these 5 parameters, a risk assessment score for PP versus TR was established. A PP-RAS score of 0 corresponds with high risk of PP vs.TR, whereas a score of 5 corresponds low risk of PP vs. TR. A score of ≤ 1 point was associated with 100 % PP, 2 points with 57 % PP and 43 % TR, 3 points with 57 % TR and 43 % PP whereas ≥ 4 points were associated with 84 % TR and 16 % PP, π=24.57, df =4, p < 0.001). Based on these 5 parameters at the time of SRS our risk assessment score could robustly differentiate between PP versusAbstract: A major challenge in the follow-up of patients managed with stereotactic radiosurgery (SRS) brain for metastases (BM) is to differentiate pseudoprogression (PP) from tumor recurrence (TR). A clinical score based on tumor and treatment related factors would be valuable when selecting appropriate treatment. Follow-up images of 97 consecutive patients treated with SRS for 406 BM were analyzed. We included 100 (24.6 %) BM in 42 (43.3 %) patients which responded either with TR (delayed growth; 53 (13.1 %) BM in 27 patients) or PP (temporary volume increase; 47 (11.6 %) BM in 15 patients). Differences between the 2 groups were analyzed and used to develop a PP risk assessment score (PP-RAS). Significant factors associated with a higher incidence of PP versus TR were: primary lung cancer vs. other primaries, BM volume < 2cc (or BM < 1.5 cm in diameter), Target cover ratio ≥ 98 % and prior radiation with SRS or WBRT. Based on the presence (0) or not (1) of these 5 parameters, a risk assessment score for PP versus TR was established. A PP-RAS score of 0 corresponds with high risk of PP vs.TR, whereas a score of 5 corresponds low risk of PP vs. TR. A score of ≤ 1 point was associated with 100 % PP, 2 points with 57 % PP and 43 % TR, 3 points with 57 % TR and 43 % PP whereas ≥ 4 points were associated with 84 % TR and 16 % PP, π=24.57, df =4, p < 0.001). Based on these 5 parameters at the time of SRS our risk assessment score could robustly differentiate between PP versus growth following SRS. The score is user-friendly and may be a useful tool to guide the decision making whether to retreat or observe at appropriate follow-up intervals. … (more)
- Is Part Of:
- Neuro-oncology. Volume 20(2018)Supplement 6
- Journal:
- Neuro-oncology
- Issue:
- Volume 20(2018)Supplement 6
- Issue Display:
- Volume 20, Issue 6 (2018)
- Year:
- 2018
- Volume:
- 20
- Issue:
- 6
- Issue Sort Value:
- 2018-0020-0006-0000
- Page Start:
- vi57
- Page End:
- vi57
- Publication Date:
- 2018-11-05
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noy148.231 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 12326.xml